Clinical trials: Bladder Cancer Treatment
Pelvic Neoplasm
BladdEr Full OR Empty for Pelvic Radiation Therapy
The present study evaluates empty and full bladder protocols for radiation therapy of genitourinary (GU), gynecological (Gyn), and gastrointestinal (GI) malignancies of the pelvis.
- Trial name
- BEFORE (NCT06651697)
- Testing
- Radiation therapy
- Where
- United States
- Volunteers
- 300 people
- Sponsor
- University of California, San Diego
Patient Satisfaction, Bladder Cancer
Ileal Conduit Versus Cutaneous Ureterostomy After Radical Cystectomy
Bladder cancer is the most common malignancy of the urinary tract and accounts for about 3.2% of all cancer worldwide where it remains the seventh most commonly diagnosed malignancy in the male population.
- Trial name
- NCT04610385
- Testing
- radical cystectomy with urinary diversion
- Volunteers
- 40 people
- Sponsor
- Assiut University
Bladder Cancer
Outpatient PDD Guided Laser Mediated Destruction of Bladder Tumors
This study compare the efficacy of conventional photodynamic (PDD) guided transurethral bladder tumor resection in the operating theatre with outpatient PDD guided laser destruction of bladder tumors through flexible cystoscopes.
- Trial name
- LaserIII (NCT02886026)
- Testing
- Bladder tumor resection using diathermia, Diode laser (980 nm) tumor destruction
- Where
- Denmark
- Volunteers
- 248 people
- Sponsor
- University Hospital Bispebjerg and Frederiksberg
Bladder Cancer Treatment
Trimodality Bladder Preservation
The aim of this study is To evaluate the outcomes of patients with muscle invasive bladder cancer managed by trimodal therapy", Neoadjuvant chemotherapy( NAC) followed by Transurethral resection of the bladder tumor then…
- Trial name
- NCT07402317
- Testing
- Transurethral resection of bladder tumor: We are aimed at Complete TURBT. Which was defined as no residual tumor, whereas incomplete TURBT
- Where
- Egypt
- Volunteers
- 97 people
- Sponsor
- Al-Azhar University
Overactive Bladder, Bladder Cancer
Severity of Overactive Bladder Symptoms in Patients After Synergo Treatment
Bladder carcinoma is the most common malignancy of the urinary tract. Approximately 75-85% of patients with bladder cancer present with a disease that is confined to the mucosa or submucosa.
- Conditions
- Overactive Bladder, Bladder Cancer, Synergo
- Trial name
- OABSYNERGO (NCT01955408)
- Testing
- Questionnaires, anticholinergic treatment, urodynamic study
- Where
- Israel
- Volunteers
- 35 people
- Sponsor
- Meir Medical Center
Bladder Cancer, Prostate Cancer
Associations Between Chemotherapy-Induced Nausea in Patients With Genitourinary, Sarcoma or Melanoma Cancers and Changes in Gut Microbiome: Potential for Precision Therapeutics
The objective of this pilot cohort study is to investigate associations between CIN and changes in gut microbiome composition profiles.
- Conditions
- Bladder Cancer, Prostate Cancer, Testicular Cancer, Bladder Carcinoma
- Trial name
- NCT05819827
- Testing
- Blood and Tissue
- Where
- 3 sites in United States
- Volunteers
- 13 people
- Sponsor
- Mayo Clinic
Bladder Cancer
Adjuvant Chemotherapy Following Radical Cystectomy to Treat Locally Advanced Bladder Cancer
Effect of adjuvant chemotherapy to control tumor progression in patients after cystectomy for locally advanced bladder cancer.
- Trial name
- NCT02074189
- Testing
- Gemcitabine, Cisplatin
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Southwest Hospital, China
Bladder Cancer
Cisplatin, Paclitaxel, and Gemcitabine in Treating Patients With Progressive Unresectable Regional or Metastatic Bladder Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00006118
- Testing
- cisplatin, gemcitabine hydrochloride, paclitaxel
- Where
- 12 sites in France, Monaco
- Sponsor
- GERCOR - Multidisciplinary Oncology Cooperative Group
Prostate Cancer Stage I, Bladder Outlet Obstruction
Transurethral Prostate Enucleation in Surveillance Protocol for Low Risk Prostate Cancer
We will compare oncological and functional outcomes of anatomical endoscopic enucleation of the prostate (AEEP) versus continued medical treatment in low-risk prostate cancer patients for whom an active surveillance protocol was…
- Trial name
- NCT05631080
- Testing
- Anatomical Endoscpic enucleation of the Prostate
- Where
- Egypt
- Volunteers
- 50 people
- Sponsor
- Mansoura University
Bladder Cancer
Radiation Therapy and Chemotherapy in Treating Patients With Stage I Bladder Cancer
RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Specialized radiation therapy that delivers a high dose of radiation directly to the tumor may kill more tumor cells and cause less damage to normal…
- Trial name
- NCT00981656
- Testing
- cisplatin, 5-fluorouracil, Mitomycin
- Where
- 13 sites in United States
- Volunteers
- 37 people
- Sponsor
- Radiation Therapy Oncology Group
Urinary Bladder Cancer
Role of Hypofractionated Radiotherapy With Concurrent Gemcitabine in Treatment of Urinary Bladder Carcinoma
Estimate the response to modified hypofractionated radiotherapy concurrent with Gemcitabine in urinary bladder cancer patients . Estimate local control, relapse free survival, overall survival and bladder preservation rate.
- Trial name
- NCT04812145
- Testing
- Chemoradiation
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Assiut University
Urothelial Carcinoma, Bladder Cancer
Trial of Adjuvant Sutent for Patients With High Risk Urothelial Carcinoma After Neoadjuvant Chemotherapy and Cystectomy
The purpose of this study is to determine whether sutent (sunitinib)is effective in preventing tumor recurrence in patients with high risk bladder cancer who have previously had chemotherapy and cystectomy (bladder removal).
- Trial name
- NCT01042795
- Testing
- Sunitinib
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- University of Michigan
Bladder (Urothelial, Transitional Cell) Cancer, Kidney (Renal Cell) Cancer
Effectiveness of a Personalized 6-month Programme on Frailty in Older Patients Treated for Bladder or Kidney Cancer.
Bladder and kidney cancers are commonly diagnosed in older adults. Surgery remains the primary treatment modality for patients with kidney or bladder cancer.
- Trial name
- FRAGECO (NCT07073703)
- Testing
- APA, Therapeutic education workshops, DAPAP
- Where
- 2 sites in France
- Volunteers
- 106 people
- Sponsor
- Centre Hospitalier Universitaire de Saint Etienne
Bladder Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter
Sunitinib as Second-Line Therapy in Treating Patients With Locally Advanced or Metastatic Transitional Cell Cancer
RATIONALE: Sunitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
- Trial name
- NCT00792025
- Testing
- sunitinib malate
- Where
- 2 sites in France
- Volunteers
- 80 people
- Sponsor
- Institut Curie
Cancer, Metastatic, Cancer
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
International registry for cancer patients evaluating the feasibility and clinical utility of an Artificial Intelligence-based precision oncology clinical trial matching tool, powered by a virtual tumor boards (VTB) program, and…
- Conditions
- Cancer, Metastatic, Cancer, Cancer of Pancreas, Cancer of Liver
- Trial name
- NCT03452774
- Testing
- Clinical Trial Matching
- Where
- 68 sites in United States, Puerto Rico
- Volunteers
- 50,000 people
- Sponsor
- Massive Bio, Inc.
Urinary Bladder Cancer, Upper Tract Urothelial Cancer
SeqUential GeMcitabine and MITomycin Treatment for Favorable High-Risk Upper Urinary Tract Urothelial Carcinoma
This Phase II clinical trial, titled "A Phase II Trial of Sequential Gemcitabine and Mitomycin Treatment for Favorable High-Risk Upper Urinary Tract Urothelial Carcinoma (SUMMIT)," aims to evaluate the safety and effectiveness of…
- Conditions
- Urinary Bladder Cancer, Upper Tract Urothelial Cancer, Urothelial Cancer
- Trial name
- NCT06822010
- Testing
- Sequential Gemcitabine and Jelmyto Treatment (Gem/Jel)
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- Rutgers, The State University of New Jersey
Non-Small Cell Lung Cancer, Urothelial Cancer
A Study of Avelumab in Combination With Axitinib In Non-Small Cell Lung Cancer (NSCLC) or Urothelial Cancer (Javelin Medley VEGF)
This is a Phase 2 study to evaluate the safety and efficacy of avelumab in combination with axitinib in patients with advanced or metastatic non-small cell lung cancer (NSCLC) who have received at least one prior platinum…
- Trial name
- NCT03472560
- Testing
- Avelumab (MSB0010718C), Axitinib (AG-013736)
- Where
- 39 sites in United States, Hungary and 6 more
- Volunteers
- 61 people
- Sponsor
- Pfizer
Urology
Efficacy and Safety of Two Bladder-preserving Treatment Durations With Disitamab Vedotin Plus Toripalimab Combination in Her2-expressing Muscle-invasive Bladder Cancer: A Phase II, Open-Label, Randomized Clinical Trial
This study aims to evaluate the efficacy of disitamab vedotin combined with toripalimab as a bladder-preserving treatment combination in patients with HER2 positive locally advanced MIBC, including one year bladder-intact DFS…
- Trial name
- NCT07151560
- Testing
- 6 cycle RC48 and JS001, 12 cycle RC48 and JS001
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Renmin Hospital of Wuhan University
Non-metastatic Muscle Invasive Bladder Cancer
Avelumab as Neoadjuvant Therapy in Subjects With Urothelial Muscle Invasive Bladder Cancers (AURA Trial)
Open-label, interventional, multi-centre, randomized phase II study. Cancer studied is non-metastatic muscle invasive bladder cancer (MIBC).
- Trial name
- AURA (NCT03674424)
- Testing
- Avelumab, cystectomy, CG
- Where
- 10 sites in Belgium, France
- Volunteers
- 137 people
- Sponsor
- Jules Bordet Institute
Non-Muscle Invasive Bladder Carcinoma, Stage 0a Bladder Cancer AJCC v8
In-home Intravesical Chemotherapy for the Treatment of Bladder Cancer, INVITE Trial
This phase Ib/II trial compares the safety, tolerability and acceptability of intravesical chemotherapy given at home to in-clinic administration in patients with non-muscle invasive bladder cancer.
- Conditions
- Non-Muscle Invasive Bladder Carcinoma, Stage 0a Bladder Cancer AJCC v8, Stage I Bladder Cancer AJCC v8, Stage 0is Bladder Cancer AJCC v8
- Trial name
- NCT06704191
- Testing
- BCG Solution, Cystoscopy, Docetaxel
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Mayo Clinic